Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Liabilities and Shareholders Equity (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $220.9 million as the latest value for Q2 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 40.77% to $220.9 million in Q2 2025 year-over-year; TTM through Dec 2025 was $494.6 million, a 54.76% decrease, with the full-year FY2024 number at $313.3 million, down 27.51% from a year prior.
  • Liabilities and Shareholders Equity was $220.9 million for Q2 2025 at Caribou Biosciences, down from $273.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $462.0 million in Q3 2021 to a low of $158.4 million in Q2 2021.
  • A 5-year average of $367.3 million and a median of $386.3 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 1127.2% in 2021, then plummeted 40.77% in 2025.
  • Caribou Biosciences' Liabilities and Shareholders Equity stood at $442.4 million in 2021, then decreased by 15.51% to $373.8 million in 2022, then grew by 15.64% to $432.2 million in 2023, then decreased by 27.51% to $313.3 million in 2024, then dropped by 29.49% to $220.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Liabilities and Shareholders Equity are $220.9 million (Q2 2025), $273.7 million (Q1 2025), and $313.3 million (Q4 2024).